中华皮肤科杂志 ›› 2023, Vol. 56 ›› Issue (11): 991-999.doi: 10.35541/cjd.20230427
中华医学会皮肤病学分会免疫学组
收稿日期:2023-07-25
修回日期:2023-09-10
发布日期:2023-11-03
通讯作者:
李巍；陆前进；姚煦
E-mail:liweiderma@fudan.edu.cn; qianlu5860@pumcderm.com.cn; dryao_xu@126.com
基金资助:Immunology Group, Chinese Society of Dermatology
Received:2023-07-25
Revised:2023-09-10
Published:2023-11-03
Contact:
Li Wei; Lu Qianjin; Yao Xu
E-mail:liweiderma@fudan.edu.cn; qianlu5860@pumcderm.com.cn; dryao_xu@126.com
Supported by:摘要： 【摘要】 老年（> 60岁）特应性皮炎在人口学特征、发病机制、临床表现、合并症等方面与儿童和成人特应性皮炎有较大不同，在诊断和治疗上有诸多需要特殊考虑的方面。因此，中华医学会皮肤性病学分会免疫学组制定老年特应性皮炎诊疗专家共识以规范和指导对老年特应性皮炎患者的诊疗和有效管理。
中华医学会皮肤病学分会免疫学组. [开放获取] 老年特应性皮炎诊疗专家共识（2023版）[J]. 中华皮肤科杂志, 2023,56(11):991-999. doi:10.35541/cjd.20230427
Immunology Group, Chinese Society of Dermatology. Expert consensus on diagnosis and treatment of atopic dermatitis in the elderly （2023）[J]. Chinese Journal of Dermatology, 2023, 56(11): 991-999.doi:10.35541/cjd.20230427
| ［1］ | 中华医学会皮肤性病学分会免疫学组, 特应性皮炎协作研究中心. 中国特应性皮炎诊疗指南（2020版）［J］. 中华皮肤科杂志, 2020,53（2）:81⁃88. doi: 10.35541/cjd.20191000. |
| ［2］ | 李巍, 王上上, 刘玉峰. 老年特应性皮炎: 一个新的临床亚型［J］. 中华皮肤科杂志, 2020,53（8）:654⁃657. doi: 10.35541/cjd.20190760. |
| ［3］ | Muto T, Hsieh SD, Sakurai Y, et al. Prevalence of atopic dermatitis in Japanese adults［J］. Br J Dermatol, 2003,148（1）:117⁃121. doi: 10.1046/j.1365⁃2133.2003.05092.x. |
| ［4］ | Saeki H, Tsunemi Y, Fujita H, et al. Prevalence of atopic dermatitis determined by clinical examination in Japanese adults［J］. J Dermatol, 2006,33（11）:817⁃819. doi: 10.1111/j.1346⁃8138.2006.00187.x. |
| ［5］ | Bozek A, Fisher A, Filipowska B, et al. Clinical features and immunological markers of atopic dermatitis in elderly patients［J］. Int Arch Allergy Immunol, 2012,157（4）:372⁃378. doi: 10. 1159/000329150. |
| ［6］ | Sybilski AJ, Raciborski F, Lipiec A, et al. Epidemiology of atopic dermatitis in Poland according to the Epidemiology of Allergic Disorders in Poland （ECAP） study［J］. J Dermatol, 2015,42（2）:140⁃147. doi: 10.1111/1346⁃8138.12731. |
| ［7］ | Salava A, Rieppo R, Lauerma A, et al. Age⁃dependent distribution of atopic dermatitis in primary care: a nationwide population⁃based study from Finland［J］. Acta Derm Venereol, 2022,102:adv00738. doi: 10.2340/actadv.v102.2287. |
| ［8］ | Laughter MR, Maymone M, Mashayekhi S, et al. The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990⁃2017［J］. Br J Dermatol, 2021,184（2）:304⁃309. doi: 10.1111/bjd.19580. |
| ［9］ | Tanei R, Katsuoka K. Clinical analyses of atopic dermatitis in the aged［J］. J Dermatol, 2008,35（9）:562⁃569. doi: 10.1111/j.1346⁃8138.2008.00524.x. |
| ［10］ | Wang S, Zhu R, Gu C, et al. Distinct clinical features and serum cytokine pattern of elderly atopic dermatitis in China［J］. J Eur Acad Dermatol Venereol, 2020,34（10）:2346⁃2352. doi: 10.1111/ jdv.16346. |
| ［11］ | Tanei R, Hasegawa Y. Atopic dermatitis in older adults: a viewpoint from geriatric dermatology［J］. Geriatr Gerontol Int, 2016,16 Suppl 1:75⁃86. doi: 10.1111/ggi.12771. |
| ［12］ | Tanei R. Atopic dermatitis in the elderly［J］. Inflamm Allergy Drug Targets, 2009,8（5）:398⁃404. doi: 10.2174/187152811090 8050398. |
| ［13］ | Williamson S, Merritt J, De Benedetto A. Atopic dermatitis in the elderly: a review of clinical and pathophysiological hallmarks［J］. Br J Dermatol, 2020,182（1）:47⁃54. doi: 10.1111/bjd.17896. |
| ［14］ | Birch J, Gil J. Senescence and the SASP: many therapeutic avenues［J］. Genes Dev, 2020,34（23⁃24）:1565⁃1576. doi: 10. 1101/gad.343129.120. |
| ［15］ | Zhou L, Leonard A, Pavel AB, et al. Age⁃specific changes in the molecular phenotype of patients with moderate⁃to⁃severe atopic dermatitis［J］. J Allergy Clin Immunol, 2019,144（1）:144⁃156. doi: 10.1016/j.jaci.2019.01.015. |
| ［16］ | Choi EH. Aging of the skin barrier［J］. Clin Dermatol, 2019,37（4）:336⁃345. doi: 10.1016/j.clindermatol.2019.04.009. |
| ［17］ | Kottner J, Lichterfeld A, Blume⁃Peytavi U. Transepidermal water loss in young and aged healthy humans: a systematic review and meta⁃analysis［J］. Arch Dermatol Res, 2013,305（4）:315⁃323. doi: 10.1007/s00403⁃012⁃1313⁃6. |
| ［18］ | Wlaschek M, Maity P, Makrantonaki E, et al. Connective tissue and fibroblast senescence in skin aging［J］. J Invest Dermatol, 2021,141（4S）:985⁃992. doi: 10.1016/j.jid.2020.11.010. |
| ［19］ | Lipozencić J, Wolf R. Atopic dermatitis: an update and review of the literature［J］. Dermatol Clin, 2007,25（4）:605⁃612, x. doi: 10.1016/j.det.2007.06.009. |
| ［20］ | Li F, Xie W, Chen Z, et al. Neuropeptide Y and receptors are associated with the pyroptosis of nucleus pulposus in aging and degenerative intervertebral discs of rats［J］. Neuropeptides, 2022,96:102284. doi: 10.1016/j.npep.2022.102284. |
| ［21］ | Langan SM, Irvine AD, Weidinger S. Atopic dermatitis［J］. Lancet, 2020,396（10247）:345⁃360. doi: 10.1016/S0140⁃6736（20）31286⁃1. |
| ［22］ | Bolognia JL, Schaffer JV, Cerroni L. Dermatology［M］. 4th ed. New York: Elsevier, 2018. |
| ［23］ | Bieber T, D′Erme AM, Akdis CA, et al. Clinical phenotypes and endophenotypes of atopic dermatitis: where are we, and where should we go?［J］. J Allergy Clin Immunol, 2017,139（4S）:S58⁃S64. doi: 10.1016/j.jaci.2017.01.008. |
| ［24］ | Yang L, Fu J, Zhou Y. Research progress in atopic march［J］. Front Immunol, 2020,11:1907. doi: 10.3389/fimmu.2020.01907. |
| ［25］ | Renert⁃Yuval Y, Del Duca E, Pavel AB, et al. The molecular features of normal and atopic dermatitis skin in infants, children, adolescents, and adults［J］. J Allergy Clin Immunol, 2021,148（1）:148⁃163. doi: 10.1016/j.jaci.2021.01.001. |
| ［26］ | Brunner PM, Israel A, Zhang N, et al. Early⁃onset pediatric atopic dermatitis is characterized by T（H）2/T（H）17/T（H）22⁃centered inflammation and lipid alterations［J］. J Allergy Clin Immunol, 2018,141（6）:2094⁃2106. doi: 10.1016/j.jaci.2018.02. 040. |
| ［27］ | Sacotte R, Silverberg JI. Epidemiology of adult atopic dermatitis［J］. Clin Dermatol, 2018,36（5）:595⁃605. doi: 10.1016/j.clindermatol. 2018.05.007. |
| ［28］ | Yousaf M, Ayasse M, Ahmed A, et al. Association between atopic dermatitis and hypertension: a systematic review and meta⁃analysis［J］. Br J Dermatol, 2022,186（2）:227⁃235. doi: 10.1111/bjd.20661. |
| ［29］ | Silverberg JI, Gelfand JM, Margolis DJ, et al. Association of atopic dermatitis with allergic, autoimmune, and cardiovascular comorbidities in US adults［J］. Ann Allergy Asthma Immunol, 2018,121（5）:604⁃612.e3. doi: 10.1016/j.anai.2018.07.042. |
| ［30］ | Paller A, Jaworski JC, Simpson EL, et al. Major comorbidities of atopic dermatitis: beyond allergic disorders［J］. Am J Clin Dermatol, 2018,19（6）:821⁃838. doi: 10.1007/s40257⁃018⁃0383⁃4. |
| ［31］ | He H, Li R, Choi S, et al. Increased cardiovascular and atherosclerosis markers in blood of older patients with atopic dermatitis［J］. Ann Allergy Asthma Immunol, 2020,124（1）:70⁃78. doi: 10.1016/j.anai.2019.10.013. |
| ［32］ | Brunner PM, Guttman⁃Yassky E, Leung DY. The immunology of atopic dermatitis and its reversibility with broad⁃spectrum and targeted therapies［J］. J Allergy Clin Immunol, 2017,139（4S）:S65⁃S76. doi: 10.1016/j.jaci.2017.01.011. |
| ［33］ | Ahn C, Huang W. Clinical presentation of atopic dermatitis［J］. Adv Exp Med Biol, 2017,1027:39⁃46. doi: 10.1007/978⁃3⁃319⁃64804⁃0_4. |
| ［34］ | 中华医学会皮肤性病学分会免疫学组, 中国医师协会皮肤科医师分会指南制定与规范委员会. 皮炎湿疹类疾病规范化诊断术语专家共识［J］. 中华皮肤科杂志, 2021,54（11）:937⁃942. doi: 10.35541/cjd.20210578. |
| ［35］ | 宋志强, 邓思思. 对老年特应性皮炎的再认识［J］. 中华医学杂志, 2023,103（32）:2470⁃2474. doi: 10.3760/cma.j.cn112137⁃20221227⁃02706. |
| ［36］ | Yue W, Cheng D, Sun Z, et al. Validation of diagnostic criteria for atopic dermatitis and proposal of novel diagnostic criteria for adult and elderly Chinese populations: a multicentre, prospective, clinical setting⁃based study［J］. Br J Dermatol, 2023,188（3）:420⁃426. doi: 10.1093/bjd/ljac097. |
| ［37］ | Chello C, Carnicelli G, Sernicola A, et al. Atopic dermatitis in the elderly Caucasian population: diagnostic clinical criteria and review of the literature［J］. Int J Dermatol, 2020,59（6）:716⁃721. doi: 10.1111/ijd.14891. |
| ［38］ | 姚煦.常用特应性皮炎严重度评估方法［J］. 中华皮肤科杂志, 2021,54（6）:539⁃541. doi: 10.35541/cjd.20200825. |
| ［39］ | 中华医学会皮肤性病学分会免疫学组. 特应性皮炎的全程管理共识［J］. 中华皮肤科杂志, 2023,56（1）:5⁃15. doi: 10.35541/cjd.20220618. |
| ［40］ | Tanei R. Atopic dermatitis in older adults: a review of treatment options［J］. Drugs Aging, 2020,37（3）:149⁃160. doi: 10.1007/s40266⁃020⁃00750⁃5. |
| ［41］ | 赵作涛, 高兴华. 中重度特应性皮炎系统药物达标治疗专家指导建议［J］. 中国皮肤性病学杂志, 2022,36（8）:855⁃864. doi: 10.13735/j.cjdv.1001⁃7089.202205115. |
| ［42］ | Teplitsky V, Mumcuoglu KY, Babai I, et al. House dust mites on skin, clothes, and bedding of atopic dermatitis patients［J］. Int J Dermatol, 2008,47（8）:790⁃795. doi: 10.1111/j.1365⁃4632.2008. 03657.x. |
| ［43］ | Katoh N, Ohya Y, Ikeda M, et al. Japanese guidelines for atopic dermatitis 2020［J］. Allergol Int, 2020,69（3）:356⁃369. doi: 10. 1016/j.alit.2020.02.006. |
| ［44］ | Wollenberg A, Kinberger M, Arents B, et al. European guideline （EuroGuiDerm） on atopic eczema ⁃ part II: non⁃systemic treatments and treatment recommendations for special AE patient populations［J］. J Eur Acad Dermatol Venereol, 2022,36（11）:1904⁃1926. doi: 10.1111/jdv.18429. |
| ［45］ | 中国中西医结合学会皮肤性病专业委员会环境与职业性皮肤病学组, 中华医学会皮肤性病学分会儿童学组, 中国老年保健医学研究会皮肤科分会. 特应性皮炎外用制剂合理应用及患者指导专家共识［J］. 中华皮肤科杂志, 2022,55（4）:281⁃288. doi: 10.35541/cjd.20210833. |
| ［46］ | Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema［J］. Health Technol Assess, 2000,4（37）:1⁃191. |
| ［47］ | Fishbein AB, Silverberg JI, Wilson EJ, et al. Update on atopic dermatitis: diagnosis, severity assessment, and treatment selection［J］. J Allergy Clin Immunol Pract, 2020,8（1）:91⁃101. doi: 10.1016/j.jaip.2019.06.044. |
| ［48］ | Papp K, Szepietowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double⁃blind studies［J］. J Am Acad Dermatol, 2021,85（4）:863⁃872. doi: 10.1016/j.jaad.2021. 04.085. |
| ［49］ | Seegräber M, Srour J, Walter A, et al. Dupilumab for treatment of atopic dermatitis［J］. Expert Rev Clin Pharmacol, 2018,11（5）:467⁃474. doi: 10.1080/17512433.2018.1449642. |
| ［50］ | Silverberg JI, Guttman⁃Yassky E, Gadkari A, et al. Real⁃world persistence with dupilumab among adults with atopic dermatitis［J］. Ann Allergy Asthma Immunol, 2021,126（1）:40⁃45. doi: 10.1016/j.anai.2020.07.026. |
| ［51］ | Patruno C, Napolitano M, Argenziano G, et al. Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real⁃life study［J］. J Eur Acad Dermatol Venereol, 2021,35（4）:958⁃964. doi: 10.1111/jdv.17094. |
| ［52］ | 贾元源, 毛秋雨, 杨婧怡, 等. 度普利尤单抗治疗中重度老年特应性皮炎临床疗效观察［J］. 中华皮肤科杂志, 2023,56（2）:125⁃129. doi: 10.35541/cjd.20220516. |
| ［53］ | 中华医学会皮肤性病学分会特应性皮炎研究中心, 中华医学会皮肤性病学分会儿童学组. 度普利尤单抗治疗特应性皮炎专家共识［J］.中华皮肤科杂志, 2022,55（6）:465⁃470. doi: 10.35541/cjd.20210885 |
| ［54］ | Jo CE, Finstad A, Georgakopoulos JR, et al. Facial and neck erythema associated with dupilumab treatment: a systematic review［J］. J Am Acad Dermatol, 2021,84（5）:1339⁃1347. doi: 10.1016/j.jaad.2021.01.012. |
| ［55］ | Brumfiel CM, Patel MH, Zirwas MJ. Development of psoriasis during treatment with dupilumab: a systematic review［J］. J Am Acad Dermatol, 2022,86（3）:708⁃709. doi: 10.1016/j.jaad.2021. 05.013. |
| ［56］ | Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate⁃to⁃severe uncontrolled asthma［J］. N Engl J Med, 2018,378（26）:2486⁃2496. doi: 10.1056/NEJMoa1804092. |
| ［57］ | Wollenberg A, Kinberger M, Arents B, et al. European guideline （EuroGuiDerm） on atopic eczema: part I ⁃ systemic therapy［J］. J Eur Acad Dermatol Venereol, 2022,36（9）:1409⁃1431. doi: 10. 1111/jdv.18345. |
| ［58］ | Chovatiya R, Paller AS. JAK inhibitors in the treatment of atopic dermatitis［J］. J Allergy Clin Immunol, 2021,148（4）:927⁃940. doi: 10.1016/j.jaci.2021.08.009. |
| ［59］ | He H, Guttman⁃Yassky E. JAK Inhibitors for atopic dermatitis: an update［J］. Am J Clin Dermatol, 2019,20（2）:181⁃192. doi: 10.1007/s40257⁃018⁃0413⁃2. |
| ［60］ | Katoh N, Ohya Y, Ikeda M, et al. Clinical practice guidelines for the management of atopic dermatitis 2018［J］. J Dermatol, 2019,46（12）:1053⁃1101. doi: 10.1111/1346⁃8138.15090. |
| ［61］ | Simon D, Bieber T. Systemic therapy for atopic dermatitis［J］. Allergy, 2014,69（1）:46⁃55. doi: 10.1111/all.12339. |
| ［62］ | 中国医师协会皮肤科医师分会自身免疫病专业委员会. 环孢素治疗免疫相关性皮肤病专家建议［J］. 中华皮肤科杂志, 2022,55（6）:471⁃479. doi: 10.35541/cjd.20210434. |
| ［63］ | Wallace DV. Treatment options for moderate to severe atopic dermatitis［J］. Allergy Asthma Proc, 2022,43（6）:474⁃493. doi: 10.2500/aap.2022.43.220076. |
| ［64］ | Fulop T, Larbi A, Kotb R, et al. Aging, immunity, and cancer［J］. Discov Med, 2011,11（61）:537⁃550. |
| ［65］ | 颜克香. 甲氨蝶呤在皮肤科的临床应用及注意事项［J］. 皮肤科学通报, 2021,38（4）:320⁃326. |
| ［66］ | Purvis D, Lee M, Agnew K, et al. Long⁃term effect of methotrexate for childhood atopic dermatitis［J］. J Paediatr Child Health, 2019,55（12）:1487⁃1491. doi: 10.1111/jpc.14478. |
| ［67］ | Du⁃Thanh A, Merlet S, Maillard H, et al. Combined treatment with low⁃dose methotrexate and initial short⁃term superpotent topical steroids in bullous pemphigoid: an open, multicentre, retrospective study［J］. Br J Dermatol, 2011,165（6）:1337⁃1343. doi: 10.1111/j.1365⁃2133.2011.10531.x. |
| ［68］ | Gori N, Chiricozzi A, Malvaso D, et al. Successful combination of systemic agents for the treatment of atopic dermatitis resistant to dupilumab therapy［J］. Dermatology, 2021,237（4）:535⁃541. doi: 10.1159/000512890. |
| ［69］ | Gerbens L, Hamann S, Brouwer M, et al. Methotrexate and azathioprine for severe atopic dermatitis: a 5⁃year follow⁃up study of a randomized controlled trial［J］. Br J Dermatol, 2018,178（6）:1288⁃1296. doi: 10.1111/bjd.16240. |
| ［70］ | Drucker AM, Ellis AG, Bohdanowicz M, et al. Systemic immunomodulatory treatments for patients with atopic dermatitis: a systematic review and network meta⁃analysis［J］. JAMA Dermatol, 2020,156（6）:659⁃667. doi: 10.1001/jamadermatol.2020. 0796. |
| ［71］ | Reddy KR, Beavers KL, Hammond SP, et al. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy［J］. Gastroenterology, 2015,148（1）:215⁃219; quiz e16⁃17. doi: 10.1053/j.gastro.2014.10.039. |
| ［72］ | Mashiah J, Karady T, Fliss⁃Isakov N, et al. Clinical efficacy of fecal microbial transplantation treatment in adults with moderate⁃to⁃severe atopic dermatitis［J］. Immun Inflamm Dis, 2022,10（3）:e570. doi: 10.1002/iid3.570. |
| ［73］ | Jiang X, Liu Z, Ma Y, et al. Fecal microbiota transplantation affects the recovery of AD⁃skin lesions and enhances gut microbiota homeostasis［J］. Int Immunopharmacol, 2023,118:110005. doi: 10.1016/j.intimp.2023.110005. |
| ［74］ | Huang R, Ning H, Shen M, et al. Probiotics for the treatment of atopic dermatitis in children: a systematic review and meta⁃analysis of randomized controlled trials［J］. Front Cell Infect Microbiol, 2017,7:392. doi: 10.3389/fcimb.2017.00392. |
| ［75］ | Mittal A, Agarwal C, Balai M, et al. Gabapentin and pregabalin in dermatology［J］. Indian J Dermatol Venereol Leprol, 2018,84（5）:634⁃640. doi: 10.4103/ijdvl.IJDVL_480_17. |
| ［76］ | 中国医师协会皮肤科医师分会过敏性疾病专业委员会, 中华医学会皮肤性病学分会特应性皮炎研究中心, 中国医疗保健国际交流促进会皮肤科分会. 特应性皮炎瘙痒管理专家共识［J］. 中华皮肤科杂志, 2021,54（5）:391⁃396. doi: 10.35541/cjd.20210056. |
| ［77］ | Zirwas MJ. Dramatic response to chloroquine and mirtazapine for recalcitrant atopic dermatitis［J］. Dermatitis, 2006,17（4）:208⁃210. doi: 10.2310/6620.2006.06013. |
| ［78］ | Sun PY, Li HG, Xu QY, et al. Lidocaine alleviates inflammation and pruritus in atopic dermatitis by blocking different population of sensory neurons［J］. Br J Pharmacol, 2023,180（10）:1339⁃1361. doi: 10.1111/bph.16012. |
| ［79］ | Kemény L, Varga E, Novak Z. Advances in phototherapy for psoriasis and atopic dermatitis［J］. Expert Rev Clin Immunol, 2019,15（11）:1205⁃1214. doi: 10.1080/1744666X.2020.1672537. |
| ［80］ | Liu L, Luo Y, Zhou M, et al. Tripterygium agents for the treatment of atopic eczema: a Bayesian analysis of randomized controlled trials［J］. Phytomedicine, 2019,59:152914. doi: 10. 1016/j.phymed.2019.152914. |
| ［81］ | Tan HY, Lenon GB, Zhang AL, et al. Efficacy of acupuncture in the management of atopic dermatitis: a systematic review［J］. Clin Exp Dermatol, 2015,40（7）:711⁃716. doi: 10.1111/ced.12732. |
| [1] | 王钰倩 乔建军 方红. 国内外斑秃诊疗指南/共识比较 [J]. 中华皮肤科杂志, 2023, 56(9): 885-888. |
| [2] | 郭昊 刘辉 张丽 朱冠男 王平 姚志荣 高兴华 陈耀龙. 特应性皮炎诊疗指南（专科医生版本、全科医生版本和患者版本）计划书[J]. 中华皮肤科杂志, 2023, 56(9): 809-814. |
| [3] | 陈春里 闫思聿 王丹 高丽华 谭丽娜 唐四元 刘伟 曾金容 鲁建云. 酸化脂肪酸酯治疗特应性皮炎样模型小鼠的疗效及机制初探[J]. 中华皮肤科杂志, 2023, 56(9): 822-831. |
| [4] | 王珊 王星宇 舒虹 张斌 石航 杨欢 钱秋芳 马红艳 梁源 赵牧童 申春平 焦磊 田晶 汪洋 谷盈 孙婧 刘盈 李萍 王华 马琳. 克立硼罗软膏早期缓解儿童特应性皮炎临床症状及改善缓解期临床症状的多中心临床研究[J]. 中华皮肤科杂志, 2023, 56(9): 815-821. |
| [5] | 陈耀龙 刘辉 姚志荣 高兴华. 提升皮肤病领域指南和共识质量的策略与建议[J]. 中华皮肤科杂志, 2023, 56(9): 805-808. |
| [6] | 刘小扬 赵琰 蔡林 张建中. 银屑病患者白细胞介素17拮抗剂治疗后出现特应性皮炎样皮疹4例分析与文献回顾[J]. 中华皮肤科杂志, 2023, 56(9): 845-848. |
| [7] | 张晓东 汪蔓雅 朱英杰 骆天德 刘小明. 荧光染色法在面部皮肤蠕形螨检查中的应用评估[J]. 中华皮肤科杂志, 2023, 56(8): 766-769. |
| [8] | 申春平 李萍 罗晓燕 梁源 刘盈 赵牧童 王珊 田晶 焦磊 汪洋 罗珍 余时娟 方晓 王华 马琳. [开放获取] 某润肤霜联合周末外用糖皮质激素对延缓儿童特应性皮炎维持期疾病复发的随机、空白对照、多中心临床研究[J]. 中华皮肤科杂志, 2023, 56(8): 756-762. |
| [9] | 袁心刚 倪思利 张建 罗晓燕 王华. 儿童黑素细胞痣的诊疗水平亟待提高[J]. 中华皮肤科杂志, 2023, 56(8): 782-786. |
| [10] | 徐西利 李东宁 段函 王菲. 青少年及成人特应性皮炎患者血浆氨基酸代谢水平分析[J]. 中华皮肤科杂志, 2023, 56(8): 742-750. |
| [11] | 中国医师协会皮肤科医师分会. [开放获取] 保湿润肤类产品应用指导专家共识（2023版）[J]. 中华皮肤科杂志, 2023, 56(8): 711-717. |
| [12] | 宋志强 陈奇权 葛兰. 从特应性皮炎发病机制谈靶向治疗进展[J]. 中华皮肤科杂志, 2023, 56(8): 718-723. |
| [13] | 渠莉田 陈锦丛 程波 苏惠春. 特应性皮炎患者外周血单个核细胞转谷氨酰胺酶2的表达与相关炎症因子及疾病严重程度的相关性[J]. 中华皮肤科杂志, 2023, 56(7): 651-656. |
| [14] | 中华医学会皮肤性病学分会银屑病专业委员会. 中国银屑病诊疗指南（2023版）[J]. 中华皮肤科杂志, 2023, 56(7): 573-625. |
| [15] | 蒋晓妍 高敏 张晓艳 刘宁远. 白细胞介素17和白细胞介素23拮抗剂治疗脓疱型银屑病研究进展[J]. 中华皮肤科杂志, 2023, 56(7): 689-692. |
|
